Defining long COVID using a population-based SARS-CoV-2 survey in California.

dc.contributor.affiliationCalifornia Department of Public Health, Richmond, CA, USA; School of Medicine, University of California, Davis, CA, USA; Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Electronic address: jmpry@ucdavis.edu.
dc.contributor.affiliationCalifornia Department of Public Health, Richmond, CA, USA.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorPry JM
dc.contributor.authorMcCullough K
dc.contributor.authorLai KW
dc.contributor.authorLim E
dc.contributor.authorMehrotra ML
dc.contributor.authorLamba K
dc.contributor.authorJain S
dc.date.accessioned2025-05-23T11:42:02Z
dc.date.issued2024-Dec-02
dc.description.abstractBACKGROUND: More than four years after the start of the COVID-19 pandemic, understanding of SARS-CoV-2 burden and post-acute sequela of COVID (PASC), or long COVID, continues to evolve. However, prevalence estimates are disparate and uncertain. Leveraging survey responses from a large serosurveillance study, we assess prevalence estimates using five different long COVID definitions among California residents. METHODS: The California Department of Public Health (CDPH) conducted a cross-sectional survey that included questions about acute COVID-19 infection and recovery. A random selection of California households was invited to participate in a survey that included demographic information, clinical symptoms, and COVID-19 vaccination history. We assessed prevalence and predictors of long COVID among those previously testing positive for SARS-CoV-2 across different definitions using logistic regression. FINDINGS: A total of 2883 participants were included in this analysis; the majority identified as female (62.5 %), and the median age was 39 years (interquartile range: 17-55 years). We found a significant difference in long COVID prevalence across definitions with the highest prevalence observed when participants were asked about incomplete recovery (20.9 %, 95 % confidence interval [CI]: 19.4-22.5) and the lowest prevalence was associated with severe long COVID affecting an estimated 4.9 % (95 % CI 4.1-5.7) of the participant population. Individuals that completed the primary vaccination series had significantly lower prevalence of long COVID compared to those that did not receive COVID vaccination. INTERPRETATION: There were significant differences in the estimated prevalence of long COVID across different definitions. People who experience a severe initial COVID-19 infection should be considered at a higher probability for developing long COVID. FUNDING: Centers for Disease Control and Prevention - Epidemiology and Laboratory Capacity.
dc.identifier.doi10.1016/j.vaccine.2024.126358
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10602
dc.sourceVaccine
dc.titleDefining long COVID using a population-based SARS-CoV-2 survey in California.

Files

Collections